Dr. Anthony Letai, the head of the National Cancer Institute (NCI), recently took the stage at a major cancer research conference in San Diego, aiming to quell significant turmoil and rumors swirling within the scientific community. For many researchers, the past year has felt like walking through a minefield, marked by policy shifts, funding uncertainties, and a palpable sense of instability from the government. Dr. Letai, new to his role since September 2025 after a distinguished career at Harvard and Dana-Farber, was there to reassure his peers, emphasizing that despite the appearance of chaos, the NCI remains “stable.” He insisted that the institute’s core mission to conquer cancer hasn’t wavered, and surprisingly, its funding is actually stronger than reported, challenging the narrative of budget cuts and a federal research enterprise in decline. It’s clear he’s stepping into a challenging leadership position, trying to re-establish confidence amidst a period of considerable unease.
The heart of the confusion, according to Dr. Letai, stemmed from a change in how the NCI and other National Institutes of Health (NIH) agencies disburse funds. While he admitted that fewer individual grants were awarded in 2025, he pointed to a new system of “lump-sum payments” for multiyear grants. Instead of researchers receiving funding year by year, they now get the full amount upfront. This shift, he argued, meant that in fiscal year 2025, the NCI actually poured “more dollars to extramural research…than at any time in the history of the National Cancer Institute.” He painted this not as a sign of trouble, but rather an evolving strategy to streamline funding, acknowledging that any significant policy shift naturally breeds “understandable confusion about charting the course ahead.” This change, while potentially beneficial in the long run, has undoubtedly created a bumpy transition for many researchers who rely on consistent, predictable funding.
However, Dr. Letai’s calm reassurances stand in stark contrast to the very real anxieties felt by countless researchers. His words echoed through a community that has experienced “tangible losses” and disruptions, not just “confusion and uncertainty.” The previous year saw terminated NIH grants halting hundreds of clinical trials, disproportionately affecting women and early-career scientists. Compounding this, research that didn’t align with the administration’s anti-diversity priorities faced active scrutiny, raising concerns about academic freedom and the pursuit of diverse scientific questions. Even with a minor budget increase for the NIH in 2026 from Congress, the agency has been notoriously slow in awarding grants and announcing new funding opportunities, leaving many in limbo. So, while Dr. Letai highlighted the positive aspects of funding changes, the lived experience for many on the ground has been one of hardship and insecurity, making his call for patience resonate differently for those facing immediate challenges.
Dr. Letai didn’t completely ignore the struggles of the past year. He specifically acknowledged the noticeable dip in R01 grants – the NIH’s primary funding mechanism – awarded to early-career researchers, a crucial demographic for the future of science. Yet, he framed this as a temporary blip, outlining a clear plan for recovery. “NCI is planning and budgeting this year to make more [early-stage investigator] awards in fiscal year 2026 and return to the levels that we were used to all throughout the 2020s,” he promised. He emphasized that once the multiyear funding model becomes routine, the same number of grants can be funded, albeit at an anticipated lower “funding rate of 11% moving forward.” He confidently declared, “It’s not an ongoing problem,” aiming to turn the page on what many saw as a crisis. His commitment to bringing funding levels back up for new scientists is a welcome relief, but concerns remain about the overall funding landscape and the competitive nature of securing grants.
A significant part of Dr. Letai’s message involved debunking what he labeled “misinformation” surrounding federal budget cuts. He directly addressed the widespread fear that President Trump’s initial proposal to slash the NIH budget by a massive 37% to 40% in 2026 had come to pass. “Yes, there was an initial proposal to cut the budget… but that didn’t come to fruition,” he clarified, adding that “What actually happened is we got a budget that was slightly higher.” Looking ahead to 2027, he noted that while Trump has again proposed an 11% cut to the overall NIH budget, the NCI itself has been untouched. Dr. Letai viewed this as a powerful indicator of the center’s “strong bipartisan support,” suggesting that in all his conversations with key political figures, the message is singular: “They just want us to cure cancer.” This focus on cancer research, he implies, offers a protective shield against broader budget battles, offering a glimmer of hope amidst political turbulence.
Despite the NCI’s perceived political immunity, the broader cancer research community, including professional organizations like the American Association for Cancer Research (AACR), isn’t letting its guard down. Robert Vonderheide, director of the Abramson Cancer Center and president-elect of AACR, echoed the sentiment that while Dr. Letai is a “huge supporter of cancer research,” the fight for funding is ongoing. Vonderheide himself spent significant time lobbying on Capitol Hill, and the AACR publicly thanked Senator Susan Collins for her support against last year’s proposed cuts. The AACR continues to advocate against Trump’s 2027 NIH budget cuts, even though the NCI is spared, because as Vonderheide explained, “There’s so much cancer research outside of the NCI.” Many cancer centers rely heavily on funding from other NIH institutes that would be affected. This highlights a crucial point: cancer research is a vast, interconnected ecosystem, and a blow to one part of the NIH can have ripple effects across the entire field. The recent announcement of $15 million in grants from the AACR, funded by Pfizer, further underscores the scientific community’s proactive efforts to secure funding when federal sources falter. It also serves as a stark reminder that even with broad bipartisan public support for increasing cancer research funding, as a recent AACR survey showed, the events of the past year served as a “wake-up that we can’t take the country’s support for cancer research for granted,” with patient voices emerging as the “most influential” in securing vital funding.